Bloomberg News

Novartis’s Biosimilar Rituxan Is ‘On Track,’ Sandoz Head Says

March 07, 2013

Novartis AG (NOVN)’s development of a version of the best-selling drug Rituxan is proceeding as planned, Jeff George, who heads the company’s Sandoz generics unit, said in an interview today.

“Our program is on track,” George said in Tokyo today. “But we’ve never given a time line as to when we are coming to market with the product.”

Companies including Boehringer Ingelheim GmbH are racing to bring a biosimilar version of the drug, also known as rituximab, to the market. The original compound, sold by Roche Holding AG (ROG) and Biogen Idec Inc. (BIIB:US), had about $7 billion in sales last year. Roche’s Chief Executive Officer Severin Schwan said in January that the introduction of Sandoz’s product may be delayed until 2016, Bloomberg Industries analysts wrote in a note.

“What I can say is that a number of competitors have faced issues with their clinical trial programs,” George said.

Sandoz is running trials in the two most important indications of the drug, rheumatoid arthritis and non-Hodgkin’s lymphoma. Rituxan is also sold as MabThera.

To contact the reporters on this story: Eva von Schaper in Munich at evonschaper@bloomberg.net; Kanoko Matsuyama in Tokyo at kmatsuyama2@bloomberg.net

To contact the editors responsible for this story: Phil Serafino at pserafino@bloomberg.net; Jason Gale at j.gale@bloomberg.net


Tim Cook's Reboot
LIMITED-TIME OFFER SUBSCRIBE NOW

Companies Mentioned

  • BIIB
    (Biogen Idec Inc)
    • $329.76 USD
    • 0.52
    • 0.16%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus